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Abstract
Background: Pragmatic randomized clinical trials are essential to determine the effectiveness of interventions in
“real-world” clinical practice. These trials frequently use a cluster-randomized methodology, with randomization at
the site level. Despite policymakers’ increased interest in supporting pragmatic randomized clinical trials, no studies
to date have reported on the unique recruitment challenges faced by cluster-randomized pragmatic trials. We
investigated key challenges and successful strategies for hospital recruitment in the Comprehensive Post-
Acute Stroke Services (COMPASS) study.
Methods: The COMPASS study is designed to compare the effectiveness of the COMPASS model versus usual
care in improving functional outcomes, reducing the numbers of hospital readmissions, and reducing caregiver strain for
patients discharged home after stroke or transient ischemic attack. This model integrates early supported discharge
planning with transitional care management, including nurse-led follow-up phone calls after 2, 30, and 60 days and an in-
person clinic visit at 7–14 days involving a functional assessment and neurological examination. We present descriptive
statistics of the characteristics of successfully recruited hospitals compared with all eligible hospitals, reasons for non-
participation, and effective recruitment strategies.
Results: We successfully recruited 41 (43%) of 95 eligible North Carolina hospitals. Leading, non-exclusive reasons for non-
participation included: insufficient staff or financial resources (n= 33, 61%), lack of health system support (n = 16, 30%), and
lack of support of individual decision-makers (n = 11, 20%). Successful recruitment strategies included: building
and nurturing relationships, engaging team members and community partners with a diverse skill mix, identifying
gatekeepers, finding mutually beneficial solutions, having a central institutional review board, sharing published pilot
data, and integrating contracts and review board administrators.
Conclusions: Although we incorporated strategies based on the best available evidence at the outset of the
study, hospital recruitment required three times as much time and considerably more staff than anticipated.
To reach our goal, we tailored strategies to individuals, hospitals, and health systems. Successful recruitment
of a sufficient number and representative mix of hospitals requires considerable preparation, planning, and
flexibility. Strategies presented here may assist future trial organizers in implementing cluster-randomized
pragmatic trials.
Trial registration: Clinicaltrials.gov, NCT02588664. Registered on 23 October 2015.
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Background
Pragmatic randomized clinical trials are essential to de-
termine the effectiveness of interventions in “real-world”
clinical practice. They provide high external validity
without compromising internal validity but present
unique challenges in design and implementation com-
pared with traditional randomized clinical trials [1]. To
help pragmatic trial organizers measure whether they
successfully incorporate pragmatism into trial design,
implementation, outcome measurement, and analysis,
international methodologists designed the Pragmatic Ex-
planatory Continuum Indicator Summary (PRECIS) tool
[2]. In its second iteration, PRECIS-2 included a compo-
nent to measure the degree to which recruitment
methods result in a study population that mirrors the
real-world target patient population [2]. In their report,
the authors of PRECIS-2 described pragmatic strategies
for patient-level recruitment. However, in an effort to
achieve direct real-world applicability, pragmatic trials
frequently use a cluster-randomized methodology, with
interventions that generally pose low risk to participants
and can be implemented as the new standard of care.
Strategies for pragmatic site-level recruitment were not
included in the PRECIS-2 report, and despite policy-
makers’ increased interest in supporting pragmatic ran-
domized clinical trials, to our knowledge, no studies to
date have reported on the unique recruitment challenges
faced by cluster-randomized pragmatic trials [3, 4].
Many randomized clinical trials—both explanatory and
pragmatic—fail to recruit participants efficiently, and
many trials are not undertaken because recruitment is
deemed too difficult [5]. McDonald et al. [6] reported
that more than two-thirds (69%) of trials failed to reach
their target sample size within the timescale and budget
originally planned. The unique design of the pragmatic
cluster-randomized trial adds additional challenges and
opportunities in recruitment. Here we share our experi-
ences with recruiting hospitals to participate in the
Comprehensive Post-Acute Stroke Services (COMPASS)
study, with the aim of informing other investigators de-
signing cluster-randomized pragmatic clinical trials.
Methods
The COMPASS study is a pragmatic, cluster-randomized
trial to evaluate the effectiveness of the COMPASS post-
acute stroke care model versus usual care in improving
self-reported functional status as well as reducing hospital
readmissions, all-cause mortality, healthcare utilization,
medication non-adherence, and caregiver strain. Detailed
methods have been published [7]. Eligible hospitals (i.e.,
clusters) included all acute care hospitals in North
Carolina with an emergency department that treated pa-
tients for stroke or transient ischemic attack and had the
capacity to identify patients concurrent with care. Eligible
patients included all patients who had been treated for
stroke or transient ischemic attack and who were
discharged directly home from the hospital.
To test the feasibility of our design and develop the
intervention, we established a single-center “vanguard
site,” Wake Forest Baptist Medical Center, a Joint
Commission-certified comprehensive stroke center with
an average of approximately 900 discharges of patients
for stroke annually [8].
Recruitment strategies presented in this manuscript
were drawn from two primary sources. Before starting
recruitment, we detailed the processes and procedures
that we would use in a manual of procedures. From
there, we documented the evolution of the recruitment
strategies employed in detailed minutes at weekly hos-
pital recruitment coordinator-led meetings. The eight-
member interdisciplinary team included a registered
nurse with hospital experience, the three principal inves-
tigators, and the statistical, project, and engagement co-
ordinators. The statistical coordinator ensured that we
recruited a representative mix of hospitals, a key element
in a truly pragmatic study, according to the PRECIS-2
rubric [2]. The recruitment coordinator and nurse each
dedicated 0.5 full-time equivalents to recruitment for
1 year. The project coordinator relayed information from
the contracts officer and the institutional review board
(IRB) officer; all three of these dedicated 0.1 full-time
equivalents throughout the year.
We originally proposed to recruit 50 hospitals over a
4 month period. In September 2015, we began by lever-
aging relationships built with the 51 hospitals already
participating in the North Carolina Stroke Care
Collaborative (NCSCC) [9, 10], 46 of which had pro-
vided letters of support for our proposal. The NCSCC is
a prospective registry of stroke patients designed to
track, measure, and improve the quality of acute stroke
care. It covers 60% of North Carolina counties and was
part of the Centers for Disease Control and Prevention’s
Paul Coverdell National Acute Stroke Registry Program
from 2002 to 2014. We then expanded recruitment to
include all 110 North Carolina hospitals through webi-
nars, teleconferences, and site visits. Between September
and December 2015, we successfully contacted key
personnel at all 51 NCSCC-affiliated hospitals and at 56
of the remaining 59 North Carolina hospitals.
Thereafter (January to September 2016), we tailored
our efforts to individual hospitals through individual
phone calls, presentations, and site visits (Fig. 1).
Through this process, 15 hospitals were deemed
ineligible because they did not admit patients for stroke
or transient ischemic attacks. Of the remaining 95 eli-
gible hospitals, 54 declined and 41 (43%) ultimately
chose to participate, as illustrated in the recruitment and
enrollment portion of the Consolidated Standards of
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Reporting Trials (CONSORT) flow diagram for clinical
trials in Fig. 2 [11]. The full CONSORT flow diagram
and CONSORT checklist are available in Additional file
1 and Additional file 2, respectively.
At each hospital, we sought to establish a primary con-
tact with whom we could work throughout the recruit-
ment and enrollment process. This contact was
generally at the president, vice president, or director
level, although job titles varied by hospital. At sites that
declined participation, we conducted a telephone inter-
view to query the reasons for non-participation. Sites
were free to report several reasons, and responses were
recorded as text and categorized as patterns emerged. At
successfully recruited sites, this contact was tasked with
confirming that the hospital had the staffing capability
to implement the intervention, given the hospital’s aver-
age annual stroke discharge volume. The intervention
required a nurse-level staff member to inform the pa-
tient of the study at discharge, complete 2, 30, and
60 day follow-up calls, and complete the functional as-
sessment during the follow-up clinic visit (7–14 days
after discharge). It also specified that a nurse practi-
tioner, physician’s assistant, or physician complete a
neurological examination at the follow-up clinic visit.
Oversight by an on-site principal investigator was also
required. All staff serving in these roles were required to
complete training on human subjects research and infor-
mation privacy and security through the Collaborative
Institutional Training Institute (CITI) [12] (or equiva-
lent) and maintain certification per institutional guide-
lines. These roles were specified in detailed job
descriptions and the letter of agreement. Additional de-
tails have been published [7].
In an effort to mimic a “real-world” environment, fi-
nancial incentives for participation are limited and were
not designed to cover the full cost of staff time [2]. All
participating hospitals receive limited per-case direct re-
imbursement for ascertaining and enrolling eligible
cases. Hospitals in the intervention arm receive add-
itional limited per-case reimbursement for completing
the follow-up visit. The 7–14 day clinic visit was de-
signed in such a way as to meet the billing requirements
for Centers for Medicare and Medicaid Services Transi-
tional Care Management (TCM) and Chronic Care
Management (CCM).
As a pragmatic, patient-centered trial, COMPASS in-
corporated patient perspectives throughout the study de-
sign, including an iterative consenting design process,
whereby stroke survivors and caregivers worked with the
vanguard hospital’s IRB office to develop a consenting
protocol that maximized participation and provided a
strongly patient-centered approach. As the intervention
changes hospitals’ structure and process of care for all
patients having had stroke or transient ischemic attack
who are discharged home, patients cannot fully opt out
Fig. 1 COMPASS study timeline for recruitment of 110 North Carolina acute care hospitals, September 2015 to September 2016. LOA, letter
of agreement
Fig. 2 Eligibility and enrollment portion of COMPASS study
CONSORT flow diagram
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without seeking care elsewhere; however, we designed a
consenting process that provided several opportunities
for education and consenting, with key points at dis-
charge and prior to the 90-day telephone survey. Inter-
viewers for the 90-day survey were blinded to hospitals’
randomization assignment. Additional details of this in-
novative consent design and methodology have been
published [7].
Informed by experience and reported benefits of cen-
tral IRBs for multicenter trials [13–15], we offered sites
the option to participate in the COMPASS central IRB
to avoid lengthy start-up delays caused by repeated IRB
reviews of the same protocol and to aid recruitment of
small hospitals without IRBs.
Once the letter of agreement was signed, IRB approval
was received, and CITI training was complete for all on-
site COMPASS staff, hospitals were randomized in pairs,
each matched with another hospital of similar annual
stroke discharge volume (<100, 100–299, 300+ patients)
and primary or comprehensive stroke center certification
status (“yes” or “no” as designated by the Joint Commis-
sion, an independent, voluntary national hospital ac-
creditation and certification organization). Using a
stepped-wedge design, hospitals were randomized to ei-
ther receive the COMPASS intervention at the begin-
ning of the study or after a period of providing their
usual care, to provide a control group [7].
A COMPASS statistician ensured enrollment of a suf-
ficient number of hospitals in each of the six strata for
stroke discharge volume and stroke center status, using
the average estimated number of patients who had
stroke or transient ischemic attack who were discharged
home each year from each hospital in sample size calcu-
lations. These estimates were confirmed with hospital
staff. Additional details have been published [7].
Results
The 41 hospitals successfully recruited to participate in
the COMPASS study are distributed across North
Carolina, with the majority located in the central “Pied-
mont” region, where much of the state’s population re-
sides (Table 1). Compared with all eligible hospitals in
North Carolina, participating hospitals were more likely
to be certified as primary or comprehensive stroke cen-
ters (59% vs. 41%) and to have higher annual stroke dis-
charge volumes (29% vs. 17%). Participating hospitals
were less likely to be in rural or small-town areas (10%
vs. 23%) but included a similar proportion of critical ac-
cess hospitals, compared with all eligible hospitals in
North Carolina.
The majority (n = 36, 88%) of hospitals utilized the
COMPASS central IRB option; only five hospitals (12%),
three of which were in the same health system, opted to
participate through internal IRBs.
Over half (61%) of the 54 hospitals that declined par-
ticipation cited insufficient staff or financial resources to
meet the staffing requirements to implement the inter-
vention (Fig. 3). Nearly one-third did not participate as a
result of a decision at the hospital system level, and one-
fifth cited the inability to organize support of hospital or
system-level decision-makers. Other reasons included
doubts regarding the additive value of participation, ad-
ministrative leadership changes, low priority placed on
improving post-acute stroke care, concerns about impact
on relationships with local primary care physicians, and
informed consent, sustainability, or manuscript author-
ship control. We did not receive responses to our re-
quest for interviews at eight hospitals and were unable
ascertain their reasons for non-participation. Key strat-
egies employed to address perceived barriers to partici-
pation are listed briefly in Fig. 3 and are described in
greater detail next.
Discussion
Although we recruited a sufficient number of hospitals
to meet statistical power requirements for the primary
outcome measures of the trial, the process took longer
and was more complex than anticipated. Ultimately, we
successfully recruited 43% of the 95 eligible hospitals
and developed strategies that should prove valuable for
other researchers planning cluster-randomized prag-
matic trials.
Although the current literature on hospital recruit-
ment is sparse, we developed initial strategies based on
the available evidence and our experiences in recruit-
ment for the NCSCC. Whicher et al. [16] and Anderson
et al. [17] discuss the importance of identifying and en-
gaging gatekeepers, particularly in recruiting large health
systems, where there may be many gatekeepers and
varying types of governance. Informed by such research,
before initiating formal recruitment, we sought contact
information for as many key clinical and administrative
leaders as we could at all 110 acute care hospitals in
North Carolina. Helpful in identifying these personnel
were NCSCC hospital contacts, local stroke organiza-
tions (North Carolina Stroke Association, North
Carolina Stroke Advisory Council and the Area Agency
on Aging), and other community partners and stake-
holders, including faith-based and counseling networks.
Additional details of community and stakeholder en-
gagement throughout the COMPASS design have been
published [18].
Patsopoulos [3] emphasized the importance of achiev-
ing a heterogeneous, representative mix of participants
and settings, which is also important for recruitment of
pragmatic trials, noting the challenge this can pose in
terms of sample size. Throughout the recruitment
process, to ensure that we achieved a pragmatic hospital
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sample with sufficient representation from each of the
six strata for stroke discharge volume and stroke center
status, power calculations helped drive the targeted re-
cruitment of hospitals in strata that had not yet met
their target sample sizes.
A common recruitment challenge in any cluster-
randomized trial is that of patient consent [1, 19].
Cluster-randomized trials frequently utilize a waiver of
consent for the intervention, with consent obtained only
for the collection of follow-up data, in an effort to en-
sure a truly representative patient population. While this
simplifies patient-level recruitment, it can add challenges
at the cluster level [1]. Further, our consent model incor-
porated stroke survivor and caregiver perspectives,
which created processes that were somewhat different
from traditional clinical trial procedures, and which
needed to be discussed with administrators at recruited
hospitals. In anticipation of these challenges, we secured
Table 1 Selected characteristics of COMPASS hospitals, compared with North Carolina acute care hospitals, 2016
All North Carolina hospitals N = 110 Eligible North Carolina hospitals N = 95 Participating hospitals N = 41
Primary or comprehensive
stroke center, a n (%)
39 (35%) 39 (41%) 24 (59%)
North Carolina Stroke Care
Collaborative participant, n (%)
Active 48 (44%) 47 (49%) 21 (51%)
Intermittent or inactive 26 (24%) 25 (26%) 11 (27%)
Never 36 (33%) 23 (24%) 9 (22%)
Critical Access Hospital, n (%) 21 (19%) 15 (16%) 5 (12%)
Geographic region, n (%)
Central Piedmont 48 (44%) 43 (45%) 18 (44%)
Western 23 (21%) 21 (22%) 11 (27%)
Eastern 39 (35%) 31 (33%) 12 (29%)
Medical school affiliation, b n (%)
Major 7 (6%) 6 (6%) 3 (7%)
Minor 12 (10%) 12 (12%) 5 (12%)
None 91 (83%) 77 (81%) 33 (80%)
2013 stroke discharge rate, n (%)
< 100 53 (48%) 39 (41%) 11 (27%)
100–299 41 (37%) 40 (42%) 18 (44%)
300+ 16 (15%) 16 (17%) 12 (29%)
Hospital bed size, n (%)
< 100 39 (35%) 29 (31%) 15 (37%)
100–299 48 (44%) 44 (46%) 16 (39%)
≥ 300 23 (21%) 22 (23%) 10 (24%)
Urban-rural classification, n (%)
Rural or small town 28 (25%) 25 (23%) 4 (10%)
Micropolitan 30 (27%) 27 (28%) 15 (37%)
Metropolitan 52 (47%) 43 (45%) 22 (54%)
Ownership, n (%)
Private, not-for-profit 53 (52%) 47 (51%) 18 (46%)
Private, for-profit 11 (11%) 10 (11%) 3 (8%)
Local 15 (15%) 14 (15%) 6 (15%)
Hospital district or authority 15 (15%) 13 (14%) 8 (21%)
Other 8 (8%) 8 (9%) 4 (10%)
Unknown or missing 8 3 2
aCertified by the Joint Commission, an independent, national, voluntary hospital accreditation and certification organization
bCenters for Medicare and Medicaid Services categories; “Minor” includes graduate or limited medical school affiliation or participation
Johnson et al. Trials  (2018) 19:74 Page 5 of 9
a dedicated member of the central IRB, who was avail-
able to work directly with local IRBs and administrators
and answer questions; thus lending confidence in the
process.
To accelerate recruitment at the cluster level, many
multicenter trials also provide participating sites with
the option of participating in a central IRB; this is now a
requirement for multicenter trials funded by the Na-
tional Institutes of Health [20]. Providing a central IRB
option was critical to meeting our goal of recruiting a
pragmatic, representative mix of hospitals, particularly at
smaller sites that do not traditionally participate in clin-
ical research or that do not have local IRBs. Also, our
central IRB coordinator reached out directly to primary
contacts at each site to establish whether the hospital
had participated in research in the past, whether it had a
local IRB, and whether that local IRB was willing to join
the central COMPASS IRB, and worked through related
concerns or challenges.
The Agency for Healthcare Research and Quality [21]
reported that hospitals are most likely to participate in a
quality improvement registry because of interest in the
research question or because it helps them fulfill
reimbursement or regulatory requirements. This report
also cited staff time and costs for data collection as a key
barrier to participation. The Institute of Medicine [22]
underscored the importance of tailoring recruitment
strategies and messages based on stakeholder perspec-
tives. Understanding that hospital administrative leader-
ship must guard financial resources and juggle
competing priorities, and that clinical personnel focus
more on additional staff time resources, we tailored re-
cruitment materials to different decision-makers. To ap-
peal to clinical staff, our materials provided staff time
estimates from pilot data at the COMPASS vanguard
site. For administrators, we emphasized potential bene-
fits, such as cost savings through bundled payments and
improved reimbursement for the follow-up visit.
Despite discussing these and other benefits of
participation with hospitals, by December 2015, we had
received only five letters of agreement. Like Rosen et al.
[23], we found that hospitals were more likely to partici-
pate in the study if they had an “entrepreneurial culture”
already in place (i.e., one that promotes taking risks,
innovation, and quality improvement); all five of the first
hospitals that signed COMPASS letters of agreement in
Fig. 3 Perceived barriers to COMPASS study participation and successful recruitment strategies, September 2015 to September 2016. IRB,
institutional review board; NIH, National Institutes of Health. a Perceived barriers are not mutually exclusive; therefore, percentages sum to >100%
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the first 4 months were hospitals that actively engaged
administrators and physician and nurse leadership at the
outset of discussions. These five hospitals, as well as 16
others indicating strong interest, also had in common
prior experience of participating in clinical research and
a clear “champion” of the project with decision-making
power.
During the first 4 months of recruitment, we also had
21 refusals. We reviewed the reasons for these refusals
and assessed our inability to make a successful connec-
tion at 39 hospitals. We developed the following strat-
egies to address these issues and improved our
remaining recruitment efforts.
Limited resources
Consistent with the current literature, the primary rea-
son that hospitals declined to participate was their con-
cern of insufficient staff or financial resources to carry
out the intervention (61%). Perceived resource concerns
varied by hospital. For example, at some sites the pri-
mary concern was whether they had a staff member to
complete case identification and enrollment; at others,
patient enrollment was feasible, but staff could not iden-
tify a provider to complete the post-acute follow-up visit.
For others, the modest financial compensation we pro-
vided was deemed insufficient to enable participation.
To overcome resource challenges, we leveraged the
study’s pragmatic design to provide flexible approaches
where needed to ensure that the intervention could be
faithfully implemented while making allowances for dif-
ferent staffing levels, financial resources, organizational
structures, cultures, and inter-institutional relationships.
For example, at one hospital that had difficulty identify-
ing staff to ascertain and enroll cases, we identified a
local paramedicine practice to serve in this role. A key
element in true pragmatism is how consistent an inter-
vention is with the “usual” organization and delivery of
care provided [2]; being able to provide this kind of
flexibility to hospitals enhanced their ability and willing-
ness to participate.
System-level decisions, competition, and politics
In the first 4 months of recruitment, two hospital sys-
tems (eight hospitals) declined participation owing to
market competition and complex institutional relation-
ships with the COMPASS vanguard hospital. Soon after,
it became clear that two more hospital systems were
leaning toward refusal for similar reasons. To avoid re-
fusal by these systems—both of which were large,
research-academic health systems—we engaged in high-
level conversations with hospital system administration.
Recruitment of a research team and partners with a di-
verse, representative mix of skills and experience is a
hallmark of a truly pragmatic trial [1], and without the
support of engaged partners throughout the state (in this
case, hospital administrative leadership with an under-
standing of the intense and complex competition for re-
search and innovative interventions), these successful
conversations would not have been possible.
Also, early on in the recruitment process, we engaged
a member of the COMPASS vanguard site’s contracts
department to work directly with hospitals’ contracts of-
ficers to agree on contract language to ensure that con-
cerns regarding the formal relationships of participating
institutions were being addressed, while retaining the fi-
delity of the COMPASS protocol.
Other types of competitive forces also posed chal-
lenges. At three hospitals that declined participation, as
well as at a number of others that did ultimately partici-
pate, the concern was raised that participation in the
COMPASS study might strain already delicate relation-
ships with community primary care physicians. These
sites were concerned that local primary care physicians
unaffiliated with the hospital might view the hospital’s
use of a single practitioner for the follow-up visit as
anti-competitive or an attempt by the hospital to “steal
patients.” To address this concern, we engaged clinical
experts (who explained how the COMPASS intervention
actually supports primary care physicians and encour-
ages follow-up visits), billing experts (who shared details
on billing codes still available to primary care physicians
even if the TCM or CCM codes were used by the
COMPASS practitioner), as well as a COMPASS family
medicine physician (who discussed this issue with stake-
holders from a primary care physician’s perspective). We
also addressed this concern by working together with
stakeholders to develop pragmatic, creative solutions
that still upheld the integrity of the intervention. For ex-
ample, at one hospital, we created two sites for the post-
discharge follow-up visit: one at the major local primary
care clinic for patients whose primary care physicians
were part of this network, and another in a hospital-
based clinic for all other patients. Having a dedicated
contracts officer to negotiate contract language to pro-
vide agreements that met these more complex, individu-
alized arrangements, while retaining the fidelity of the
COMPASS protocol, was instrumental.
Unconvinced of additive value
Nine hospitals (17%) declined participation because they
did not believe the COMPASS intervention would pro-
vide sufficient value beyond their usual care practices.
At some sites this appeared to be due to a lack of under-
standing of the clinical value of the intervention and the
science behind it, while at others there appeared to be a
lack of understanding or confidence in the financial
value of the intervention, particularly given the limited
financial incentives provided by pragmatic trials such as
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ours [2]. To address this, we matched the skills and ex-
pertise of COMPASS team members with those of hos-
pital decision-makers. For example, in sites where
neurology practices were considered for the post-acute
follow-up site, the COMPASS neurologist shared first-
hand experience as to how this could work in practice.
Likewise, COMPASS billing specialists and clinicians
from the vanguard site responded to concerns about
long-term financial value and sustainability. A particu-
larly valuable resource was the published pilot data from
our vanguard site, indicating that the COMPASS care
model was associated with a 48% reduction in 30 day
hospital readmissions [8].
Essential in this process was determining the perceived
drivers and barriers for each stakeholder, finding the
point of intersection of our interests, and creating prag-
matic, individualized strategies. For example, through
discussions with administrators at one community ac-
cess hospital, we found that our partnership could help
the hospital improve its visibility and position in the
community by demonstrating its commitment to provid-
ing innovative, high-quality stroke care.
Other barriers
Hospitals that signed letters of agreement early in re-
cruitment were those with which we had established a
strong working relationship through the NCSCC and
engaged a clear “champion” (i.e., a decision-maker with
a dedication to improving stroke care, willingness to
consider a new approach, and institutional clout). At
other hospitals, however, identifying and establishing
relationships with gatekeepers was less straightforward.
While some hospitals took a collaborative approach to
decision-making, involving various clinical and adminis-
trative leaders, others employed a single decision-maker.
At nine eligible hospitals, our failure to cultivate buy-in
from a single gatekeeper resulted in refusal to partici-
pate. Also, while decision-making at some hospitals was
controlled at the hospital system level, at others, individ-
ual hospitals were free to make their own decisions
about participation.
At hospitals where we had difficulty identifying or es-
tablishing relationships with gatekeepers, we had success
with “relational recruiting” by leveraging community
partnerships. With its patient-centered focus, COMPASS
has strong relationships with community stakeholders
throughout the state, who were actively involved in the
design and implementation of COMPASS and were a
critical resource for helping us form relationships at hos-
pitals where we did not previously have a relationship.
Similarly, in a volatile market for hospital ownership and
management, leadership changed at a number of hospi-
tals during the recruitment period, and these community
partners were also helpful in establishing relationships
with new leadership and confirming community buy-in
for our study.
While our aim is to provide strategies that will be
helpful to a broad array of trial organizers designing
pragmatic cluster-randomized trials, our findings are
limited to the experiences of one trial and may not be
generalizable to trials with different study populations,
provider types, or intervention requirements.
Conclusions
Although our recruitment process took three times as
long as anticipated and considerably more staff re-
sources, we successfully recruited 43% of eligible North
Carolina hospitals and enrolled a sufficient number of
cluster units to meet our design requirements. Through
this process, we learned valuable lessons in how to re-
cruit hospitals for a multicenter pragmatic randomized
clinical trial.
Building and nurturing relationships was paramount
throughout, from identifying stakeholders and gate-
keepers, building a team with a diverse and representa-
tive skill mix, and engaging partners and team members
in discussions with decision-makers. Essential in this
process was the importance of listening, focusing on the
stakeholder perspective, building trust, and seeking mu-
tually beneficial solutions. Further, providing a central
IRB option, having IRB and contracts team members,
and sharing results and experiences from pilot work
were valuable recruitment strategies. Successful site-
level recruitment requires significant preparation, plan-
ning, and flexibility. We hope that the strategies we de-
veloped as our recruitment efforts evolved will assist
future trial organizers in designing strong cluster-
randomized pragmatic trial recruitment methodologies.
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